

**Session Title:** #236: Advances in Prevention of Major Malignancies

**Session Type:** Extended Education Session

**Date:** Friday, June 4

**Location:** E354b

**Time:** 1:00 PM - 3:15 PM

- Advances in Prevention of Major Malignancies  
*Victor G. Vogel, MD*
  - 5-alpha reductase inhibitors for prostate cancer prevention  
*Ian Thompson, MD*
  - Chemoprevention of colorectal cancer  
*Monica M. Bertagnolli, MD*
  - SERMs in the Prevention of Breast Cancer  
*Jack Cuzick, PhD*
- 

**Session Title:** #72: Micronutrient Supplementation versus Dietary Modification of Cancer Prevention: Which Is Better?

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** S100b

**Time:** 8:00 AM - 9:15 AM

- Epidemiology versus clinical trials as evidence for propensity of dietary components/micronutrients to prevent cancer  
*Peter Gann, MD, ScD*
- The use of antioxidant micronutrient supplements for cancer prevention: lessons from SELECT  
*Eric A. Klein, MD*
- Vitamin D: should we be supplementing to prevent cancer?  
*John A Milner, PhD*

**Session Title:** #195: Cancer Prevention/Epidemiology

**Session Type:** General Poster Session

**Date:** Saturday, June 5

**Location:** S Hall A2

**Time:** 8:00 AM - 12:00 PM

1A #1534-High prevalence of *BRCA1/2* germline mutations in female breast cancer patients with triple-negative phenotype (TNBC) and family history.

*Cristina Saura*

1B #1535-Prospective screening for Lynch syndrome (LS) in a cohort of colorectal cancer (CRC) surgical patients in a community hospital.

*Paul R. Duncan*

1C #1536-Effect of BRCA1 gene and estrogen-receptor &alpha; on regulation of serum estradiol levels in women with breast cancer.

*Ja Yeon Kim*

1D #1537-Association of death receptor 4 variant (Glu228Ala) with ovarian cancer risk in BRCA1-mutation carriers.

*Michelle G Dick*

1E #1538-Breast cancer gene expression profile in young women who are noncarriers of BRCA1/2 mutations with and without familial history.

*Dirce Maria Carraro 1*

1F #1539-Publication bias in translational research and number of polymorphisms analyzed in genetic association studies.

*Lampriani Tsali*

1G #1540-MUTYH gene mutations in Spanish individuals with multiple colorectal adenomas without APC gene mutation.

*Ana Isabel Ferrer*

1H #1541-Association between *XRCC1* gene haplotype tagging single nucleotide polymorphisms and non-small cell lung cancer in Korean patients.

*Gyeong-won Lee*

2A #1542-Mutation position in BRCA-associated breast cancers.

*Funda Meric-Bernstam*

2B #1543-Association of HER2 655 ile&rarr;Val polymorphism with pathological response to neoadjuvant chemotherapy and trastuzumab in breast cancer.

*Alma M. Astorga*

2C #1544-Is lobular breast cancer mainly inherited from the father?

2D #1545-Gene expression profiles in non-small cell lung cancers (NSCLCs) and in corresponding healthy lung tissues in smokers versus nonsmokers.

*Amelia Szymanowska-Narloch*

2E #1546-Pilot program of fast-track germline genetic analyses as part of integrated breast, ovarian, or gastrointestinal personalized cancer care program.

*Olivier Caron*

2F #1547-Disparities in referral by risk profile for genetic counseling of high-risk individuals: A disease-specific analysis of mutation frequencies of 1,193 patients presenting for presumptive hereditary breast ovarian cancer (HBOC) or colorectal cancer syndromes (CCS).

*Iuliana Shapira*

2G #1548-Characterization of a major colon cancer susceptibility locus (Ccs3) on mouse chromosome 3.

*Charles Meunier*

2H #1549-Analysis of plasma proteome from BRCA1/BRCA2 mutation carriers as modifier risk factor of breast cancer.

*Ana Custodio*

3A #1550-A unique community-based family cancer registry.

*Nashat Y. Gabrail*

3B #1551-Promoter methylation of p16INK4A, RASSF1A, and RAR2b genes in tumor DNA from patients with breast cancer (BC) in correlation with clinical recurrence.

*Soultana Voyatzi, BSc*

3C #1552-Type II diabetes and breast cancer.

*Kirsten D Erickson*

3D #1553-Does dietary estrogen intake from meat relate to the incidence of hormone-dependent cancers?

*Yasushi Handa, MD, PhD*

3E #1554-A multi-analyte serum test for the early diagnosis of non-small cell lung cancer.

*Michael S. Vercillo*

3F #1555-Lung cancer risk and polymorphisms in UGT1A6.

*Ley-Fang Kua*

3G #1556-Breast density and calculated breast cancer risk.

*Farrah B. Khan*

3H #1557-Method of detection of DCIS to predict HER2 overexpression.

*Simone Schrading*

4C #1560-The accuracy of the HPV-associated diseases risk assessment inventory for detecting cervical dysplasias in medically underserved women in the United States.

*Mfon Samuel Cyrus-David*

4D #1561-Economic value of disability adjusted life years lost to cancers: 2008.

*Rijo M John*

4E #1562-The association between the use of statin and breast cancer recurrence.

*Young Kwang Chae*

4F #1563-A prospective study of combined colon and endometrial cancer screening in women with Lynch syndrome: A novel patient-centered approach.

*Marilyn Huang*

4G #1564-Factors influencing long-term altered quality of life, sexual functioning, and menopausal symptoms after prophylactic bilateral salpingo-oophorectomy (PBSO) among high-risk women (wm).

*Cyril Touboul*

4H #1565-Influence of thiozolidinediones (TZD) exposure on the progression of oral leukoplakia (L) and erythroplakia (E) to the development of head and neck cancer (HNC).

*Anuradha Kunthur*

5B #1567-High-precision tissue acquisition in the evaluation of breast microcalcifications.

*Jaak Janssens*

5C #1568-Barriers to colorectal cancer screening among African American population.

*Zaw Min Bo*

5D #1569-Determinants of low cell yield in random fine needle aspiration (rFNA) procedures of the breast in healthy women unselected by risk.

*Seema Ahsan Khan, MD, FACS, MPH*

5E #1570-Knowledge of cancer risk factors.

*Karen Maxwell Gil*

5F #1571-Mammography utilization in women age 40 to 49: The French EDIFICE survey.

*François Eisinger*

5G #1572-Young age at first live birth and long duration of breast feeding: Are they universally accepted protective factors against breast cancer? A case control study of the cancer research group in Pakistan.

*Misbah Masood*

5H #1573-Do Asian breast cancer patients younger than age 40 have more aggressive biologic characteristics than their western counterparts? A comparison between Shanghai and Vienna.

*Muy-Kheng Maria Tea, MD*

6A #1574-Fecundity after childhood cancer: A nationwide, population-based study.

*Milada Cvancarova*

6B #1575-Trends in incidence and location of colorectal cancer in the colonoscopy era.

*Dianne Pulte*

6C #1576-Predictors of independent living status in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

*Alicia Kunin-Batson*

6D #1577-Differing age patterns in chronic myeloid leukemia by racial ethnic group.

*Adam M Mendizabal*

6E #1578-Characterization of 25-OH vitamin D (Vit D) and factors associated with obesity in patients with high-risk breast cancer (BC): NCIC CTG MA.21.

*Elena V Tsvetkova, MD*

6F #1579-Risk of metachronous contralateral testicular germ cell tumor (met-TGCT) among 7,248 Norwegian patients (1953-2007).

*Kristine Engen Andreassen*

6G #1580-The effect of age on delay in diagnosis and stage of breast cancer.

*Ann H. Partridge, MD*

6H #1581-Innate immunity-related sequence variants as predictors of breast cancer risk among women of African descent.

*Kevin Sean Kimbro*

7A #1582-Is tumor size important in HER2-positive breast cancer?

*Carol Parise*

7B #1583-Incidence of early-onset multiple myeloma among families with endometrial carcinoma.

*Ashwin R. Sama, MD*

7C #1584-Breast cancer and high-risk diagnosis in core biopsies stratified by ethnicity.

*Elizabeth Min Hui Kim*

7D #1585-Epidemiologic risk factors associated with breast cancer subtypes.

*Arvind Bambhroliya*

7E #1586-The influence of ER on small HER2-positive invasive breast cancers.

*Vincent Caggiano*

7F #1587-Frequency of L858R and D746-750 EGFR mutations in 411 Caucasian patients with non-small cell lung cancer measured by mutation-specific antibodies.

*Anastasios T. Dimou*

7G #1588-A significant dietary change after breast cancer diagnosis: Early results of a United Kingdom prospective multicenter study.

*Louiza Sofia Velentzis*

7H #1589-Pathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study.

*Conleth Murphy*

8A #1590-Mortality for non-AIDS-defining cancers among people with AIDS.

*Antonella Zucchetto*

8B #1591-Clinical and pathologic characteristics of Hispanic breast cancer patients in a tertiary care safety net hospital.

*Theresa Marguerite Lee, MD*

8C #1592-Patterns of antidepressant use among women initiating tamoxifen therapy for the treatment of breast cancer in Ontario, Canada.

*Catherine M Kelly, MRCP, MSc*

8D #1593-Risk for subsequent breast cancer after lobular carcinoma in situ: Do clinical factors matter?

*Shirin Muhsen*

8E #1594-Longitudinal self-reported and serum-based assessment of tobacco or nicotine use in head and neck cancer patients during definitive radiotherapy or chemoradiotherapy.

*Mahesh R. Kudrimoti*

8F #1595-Survival among never and ever smokers with lung cancer in the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study.

*Christelle Clément-Duchêne*

8G #1596-Characteristics and behavior of invasive breast cancer developed despite prior oophorectomy.

*James Ryan Nitzkowski*

8H #1597-Incidental finding of pulmonary nodule on CT pulmonary angiogram (CTPA) in view of current surveillance recommendations: Is any lung cancer screening protocol applicable?

*Orlando C Enrizo, MD*

9A #1598-Prevalence of anal squamous intraepithelial lesions in HIV-positive and HIV-negative men who have sex with men in Thailand.

*Thep Chalermchai*

9B #1599-Evaluation of machine learning versus Cox regression in identification of factors predicting recurrence following resection of non-small cell lung cancer.

*Jaine K Blayney*

9C #1600-Recurrence pattern in early-stage breast cancer in a minority cohort.

*Shylandra B. Sreenivasappa*

9D #1601-Influence of market access conditions on utilization of innovative drugs in Europe: The cases of trastuzumab and cetuximab.

*Jean-Louis Misset*

9E #1602-Molecular profiles of breast cancer in Ilorin, Nigeria.

*Kayode Adebamiji Adeniji, BSc, MBChB*

9F #1603-Colon cancer disparities: A SEER-based analysis of epidemiologic data on Asian and Pakistani immigrants in the United States.

*Rubayat Naila Rahman*

9G #1604-Analysis of the geographical distribution of cancer in Israel.

*Aviad Zick*

9H #1605-Mammography-detected breast cancer among 40-49-year-old patients at a community-based cancer center: 1990-2008.

*Judith April Malmgren*

10A #1606-Thymic malignancies (TM) in the United States: A population-based study of incidence and survival trends.

*Matthew A Gubens, MD, MS*

10B #1607-Comorbidities of the underserved and minority patient with cancer presenting to a public safety-net hospital: A deterrent for clinical trial participation?

*Steven N. Wolff*

10C #1608-Characteristics of adult osteosarcoma patients: Results from an ongoing postmarketing drug safety surveillance study.

*Kirk Midkiff, MPH*

**Session Title:** #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

**Session Type:** Special Session

**Date:** Saturday, June 5

**Location:** N Hall B1

**Time:** 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

*Daniel D. Von Hoff, MD*

**Session Title:** #120: Sonic Hedgehog Pathway Inhibitors for Skin Cancer Prevention

**Session Type:** Meet the Professor Session

**Date:** Saturday, June 5

**Location:** E451b

**Time:** 1:00 PM - 2:15 PM

- Sonic Hedgehog Pathway Inhibitors for Skin Cancer Prevention

*Aleksandar Sekulic, MD, PhD*

**Session Title:** #100: The Global Burden of Cancer: The Worldwide Challenge of Cancer Control

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** S100b

**Time:** 1:15 PM - 2:30 PM

- Causes of preventable cancer in the world: from tobacco to tanning boxes (the expanding list of IARC class I carcinogens)

*Donald M Parkin, MD*

- Tobacco as a cause of worldwide cancer mortality

*Prabhat Jha, MD, D.Phil.*

- Prevention of hepatocellular carcinoma via universal vaccination against hepatitis B

*Mei-Hwei Chang, MD*

**Session Title:** #111: Aspirin and Non-steroidal Anti-inflammatory Drugs for Colorectal Cancer Prevention

**Session Type:** Meet the Professor Session

**Date:** Saturday, June 5

**Location:** E451b

**Time:** 4:45 PM - 6:00 PM

- Aspirin and Non-steroidal Anti-inflammatory Drugs for Colorectal Cancer Prevention

*John A. Baron, MD*

**Session Title:** #167: Highlights of the Day I including Clinical Trials Participation Awards

**Session Type:** Highlights of the Day

**Date:** Sunday, June 6

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

*Everett E. Vokes, MD*

- Clinical Trials Participation Awards

*Douglas W. Blayney, MD*

- Discussion: Lymphoma and Plasma Cell Disorders

*Bruce D. Cheson, MD*

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

*Alan B Sandler, MD*

- Discussion: Patient and Survivor Care

*Gretchen Genevieve Kimmick, MD*

- Discussion: Melanoma/Skin Cancers

*F. Stephen Hodi, MD*

**Session Title:** #101: The Global Status of HPV Vaccination

**Session Type:** Education Session

**Date:** Sunday, June 6

**Location:** S100b

**Time:** 8:00 AM - 9:15 AM

- Barriers to the introduction of HPV vaccines into the developing world: should boys be vaccinated?

*Mark A. Kane, MD, MPH*

- HPV vaccines for the developing world: review and new approaches to broaden HPV coverage and reduce vaccination costs

*Patti Gravitt, MS, PhD*

---

**Session Title:** #146: Cancer Prevention/Epidemiology

**Session Type:** Oral Abstract Session

**Date:** Sunday, June 6

**Location:** S100b

**Time:** 9:30 AM - 12:30 PM

- Cancer Prevention/Epidemiology

*Eva Szabo, MD*

- Cancer Prevention/Epidemiology

*Frank Sinicrope, MD*

- #1500-Lynch syndrome *TACSTD1* family with predominant colorectal cancer.

*Henry T. Lynch, MD*

- #1501-Association of Lynch syndrome and risk of invasive cervical cancer.

*Yoland Catherine Antill*

- Discussion

*Stephen B. Gruber, MD, PhD*

- #1502-Long-term survival among 298 Hodgkin lymphoma (HL) patients who develop breast cancer (BC): A population-based study.

*Michael T Milano*

- #1503-Diabetes, obesity, and survival in a large cohort of early-stage breast cancer patients.

*Sharon Hermes Giordano, MD*

- #1504-Genetic variants in the telomere maintenance pathway as predictors of second primary tumors and recurrence of early-stage head and neck cancer.

*Joshua Y Chang*

- #1505-A short-term biomarker modulation prevention study of simvastatin in women at increased risk for breast cancer.

*Michaela Jane Higgins, MBChB, MRCP*

- #1506-Characterizing benign breast disease in women at high risk for breast cancer.

*Sarah A Israel*

- #1507-Breast cancer outcome and estrogen plus progestin use in postmenopausal women.

*Rowan T. Chlebowski*

- Discussion

*Powel H Brown, MD, PhD*

---

**Session Title:** #132: Lifestyle and Pharmacologic Therapeutics in Colorectal Cancer Survivors: What to Do after Adjuvant Therapy?

**Session Type:** Clinical Problems in Oncology Session

**Date:** Sunday, June 6

**Location:** E451a

**Time:** 11:30 AM - 12:45 PM

- Pharmacologic interventions to lower the risk of tumor recurrence in patients with resected colorectal cancer

*David P. Ryan, MD*

- Beyond standard surgery and chemotherapy to lower the risk of tumor recurrence in patients with resected colorectal cancer

*Jeffrey A. Meyerhardt, MD, MPH*

---

**Session Title:** #143: Plenary Session including Science of Oncology Award and Lecture

**Session Type:** Plenary Session

**Date:** Sunday, June 6

**Location:** N Hall B1

**Time:** 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture

*Douglas W. Blayney, MD*

- Plenary Session including Science of Oncology Award and Lecture

*Daniel F. Hayes, MD*

- Plenary Session including Science of Oncology Award and Lecture

*Frank McCormick, PhD, FRS*

- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

*Robert A Burger*

- Discussion

*Elizabeth A. Eisenhauer, MD*

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

*Elisabeth A. Quoix*

- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).

*Yung-Jue Bang*

- Discussion

*Martin J. Edelman, MD*

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

*Steven O'Day, MD*

- Discussion: Ipilimumab: The light at the end of the tunnel?

*Vernon K Sondak, MD*

**Session Title:** #99: The Evolution of a Disease: How Does the Changing Epidemiology of Esophagogastric Cancers Affect Treatment Decisions?

**Session Type:** Education Session

**Date:** Sunday, June 6

**Location:** E Hall D1

**Time:** 4:45 PM - 6:00 PM

- Understanding the evolution in epidemiology of esophago-gastric cancer.

*Johanna C. Bendell, MD*

- The molecular continuum of Barrett's esophagus to esophagogastric cancer.

*Jason L Hornick, MD, PhD*

- Using the newest molecular markers in prognosis and risk stratification.

*Janusz Jankowski, PsyD*

**Session Title:** #168: Highlights of the Day II including Partners in Progress Award

**Session Type:** Highlights of the Day

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award  
*Kim Allyson Margolin, MD*
- Highlights of the Day II including Partners in Progress Award  
*Douglas W. Blayney, MD*
- Partners in Progress Award Recipient  
*Ellen V. Sigal, PhD*
- Discussion: Genitourinary (Prostate) Cancer  
*Nicholas J. Vogelzang, MD*
- Discussion: Gastrointestinal (Colorectal) Cancer  
*Howard S. Hochster, MD*
- Discussion: Gynecologic Cancer  
*Claire F. Verschraegen, MD*
- Discussion: Myeloma  
*Jean L. Harousseau, MD*
- Discussion: Cancer Prevention/Epidemiology  
*Scott Michael Lippman, MD*

**Session Title:** #141: Treatment of Barrett's Esophagus to Prevent Esophageal Cancer

**Session Type:** Clinical Problems in Oncology Session

**Date:** Monday, June 7

**Location:** E451a

**Time:** 9:45 AM - 11:00 AM

- Esophageal resection for high-grade dysplasia and superficial cancer  
*Hiran C. Fernando, MD, MBBS*
- Multimodality approaches for endoscopic ablation of Barrett's esophagus  
*Kenneth K Wang, MD*
- Risk stratification, chemoprevention and early detection in Barrett's esophagus

**Session Title:** #335: Cancer Prevention/Epidemiology

**Session Type:** Poster Discussion Session

**Date:** Monday, June 7

**Location:** E450b

**Time:** 2:00 PM - 6:00 PM

- Cancer Prevention/Epidemiology

*Marie Wood, MD*

- Cancer Prevention/Epidemiology

*Kala Visvanathan, MD, MHS*

1 #1509-Impact of early detection strategies on cancer mortality in germline *TP53* mutation carriers in Li-Fraumeni syndrome.

*Anita Villani*

2 #1510-PTEN hamartoma tumor syndrome (PHTS): Clinical characteristics, onco-phenotype, and molecular analysis.

*Mrinal M. Patnaik*

3 #1511-Prevalence of BRCA1 mutations among 284 women with triple-negative breast cancer.

*Florentia Fostira*

4 #1512-Primary fallopian tube lesions in *BRCA* mutation carriers undergoing risk-reducing surgery.

*Fanny Dao*

5 #1513-Noncancer endpoints in *BRCA1/2* carriers after risk-reducing salpingo-oophorectomy.

*Justine Cohen, DO*

6 #1514-Characterization of new Ashkenazi Jewish founder mutations in *MSH6* causing Lynch syndrome.

*Leon Raskin*

7 #1515-What size tumors should we detect as early-stage lung cancers in CT screening? Stage-size relationship in long-term repeated screening over 15 years.

*Nobuhiko Seki*

8 #1516-Assessment of overdiagnosis in CT screening for lung cancer.

*Giulia Veronesi*

9 #1517-Prospective evaluation of whole-body cancer screening with multiple modalities including FDG-PET: Results from annual screening for 5 years in 1,197 healthy volunteers.

*Sadahiko Nishizawa, MD, PhD*

10 #1518-Optically guided surgical approach and the outcome of early-stage